These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 329858)

  • 41. Suppression of prolactin secretion during ovarian hyperstimulation is followed by elevated serum levels of endometrial protein PP14 in the late luteal phase.
    Seppälä M; Martikainen H; Rönnberg L; Riittinen L; Kauppila A
    Hum Reprod; 1989 May; 4(4):389-91. PubMed ID: 2745669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bromocriptine in polycystic ovarian disease: a controlled clinical trial.
    el Tabbakh GH; Loutfi IA; Azab I; Rahman HA; Southren AL; Aleem FA
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):301-6. PubMed ID: 3279350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Premenstrual syndrome and bromocriptine].
    Tolino A; Cardone A; De Conciliis B; Mastrantonio P
    Riv Ital Ginecol; 1977; 58(5):379-83. PubMed ID: 576043
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome.
    Baker ER; Best RG; Manfredi RL; Demers LM; Wolf GC
    J Assist Reprod Genet; 1995 Mar; 12(3):205-9. PubMed ID: 8520187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bromocriptine increases plasma estradiol-17 beta concentration in amenorrhea patients with normal serum prolactin.
    Seppälä M; Unnérus HA; Hirvonen E; Ranta T
    J Clin Endocrinol Metab; 1976 Aug; 43(2):474-7. PubMed ID: 950375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of bromocriptine on menstrual cycle length.
    Smith SK; Sobowale O; Lenton EA; Cooke ID
    Br J Obstet Gynaecol; 1984 Mar; 91(3):251-5. PubMed ID: 6422976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isolating with physical restraint low status female monkeys during luteal phase might make an appropriate premenstrual depression syndrome model.
    Qiao M; Zhao Q; Zhang H; Wang H; Xue L; Wei S
    J Affect Disord; 2007 Sep; 102(1-3):81-91. PubMed ID: 17258814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group.
    Magill PJ
    Br J Gen Pract; 1995 Nov; 45(400):589-93. PubMed ID: 8554838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study.
    Rocha Filho EA; Lima JC; Pinho Neto JS; Montarroyos U
    Reprod Health; 2011 Jan; 8():2. PubMed ID: 21241460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prolactin levels and bromocriptine treatment of short luteal phase.
    Lehtovirta P; Arjomaa P; Ranta T; Laatikainen T; Hirvonen E; Seppälä M
    Int J Fertil; 1979; 24(1):57-60. PubMed ID: 37181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study.
    LeWitt PA; Gopinathan G; Ward CD; Sanes JN; Dambrosia JM; Durso R; Calne DB
    Neurology; 1982 Jan; 32(1):69-72. PubMed ID: 7033825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bromocriptine for severe mastalgia.
    Mansel RE; Preece PE; Hughes LE
    Br Med J; 1977 May; 1(6072):1356. PubMed ID: 577188
    [No Abstract]   [Full Text] [Related]  

  • 53. Progesterone and the premenstrual syndrome: a double blind crossover trial.
    Dennerstein L; Spencer-Gardner C; Gotts G; Brown JB; Smith MA; Burrows GD
    Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1617-21. PubMed ID: 3924191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prolactin suppression by bromocriptine stimulates aromatization of testosterone to estradiol in women.
    Martikainen H; Rönnberg L; Puistola U; Tapanainen J; Orava M; Kauppila A
    Fertil Steril; 1989 Jul; 52(1):51-4. PubMed ID: 2744187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of alpha-tocopherol on premenstrual symptomatology: a double-blind study. II. Endocrine correlates.
    London RS; Sundaram G; Manimekalai S; Murphy L; Reynolds M; Goldstein P
    J Am Coll Nutr; 1984; 3(4):351-6. PubMed ID: 6238991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prolactin response to thyrotropin-releasing hormone as a guideline for cyclical mastalgia treatment.
    Rea N; Bove F; Gentile A; Parmeggiani U
    Minerva Med; 1997 Nov; 88(11):479-87. PubMed ID: 9433398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of bromocriptine and pyridoxine in premenstrual tension syndrome.
    Sharma P; Kulshreshtha S; Singh GM; Bhagoliwal A
    Indian J Physiol Pharmacol; 2007; 51(4):368-74. PubMed ID: 18476391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intermittent bromocriptine treatment for the induction of ovulation in hyperprolactinemic patients.
    Bennink HJ
    Fertil Steril; 1979 Mar; 31(3):267-72. PubMed ID: 571359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease.
    Mansel RE; Preece PE; Hughes LE
    Br J Surg; 1978 Oct; 65(10):724-7. PubMed ID: 361149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolactin changes in maternal plasma following termination by vacuum curettage and the effect of bromocriptine treatment on these changes.
    Ylikorkala O; Rönnberg L
    Br J Obstet Gynaecol; 1980 Oct; 87(10):911-5. PubMed ID: 7426491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.